Literature DB >> 16999772

Conformational analysis of r207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach.

Sandrine Gaurrand1, Stéphanie Desjardins, Christophe Meyer, Pascal Bonnet, Jean-Michel Argoullon, Hassan Oulyadi, Jérôme Guillemont.   

Abstract

R207910 is an enantiomeric compound from a new class of antimycobacterial agents, the diarylquinolines [Science; 307:223 (2005)]. As enantiospecific interaction is required for biologic activity, we have undertaken a combined nuclear magnetic resonance and molecular modeling study to gain new insights into its conformation in solution and its absolute configuration. A conformational analysis using a Monte-Carlo method has been performed on each of the four possible stereomers of this compound leading to the identification of their most stable conformation. Additional ab initio calculation was performed with emphasis on the strength of the observed intramolecular hydrogen bond. Simultaneously, a complete structural identification has been carried out by a set of monodimensional and bidimensional (1)H-(13)C-NMR experiments. Determination of inter-proton distances has been achieved by a series of (1)H-(1)H ROESY NMR experiments with different mixing times followed by a volume quantification of the correlations peaks. These experimental data were compared with the theoretical distances obtained from the conformational analysis. The remarkable match shows that R207910 adopts one of the low-energy conformations predicted by molecular modeling and belongs to the (RS, SR) couple of diastereoisomers. A posteriori validation of our approach has been performed by X-ray structure determination that concluded for the RS configuration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16999772     DOI: 10.1111/j.1747-0285.2006.00410.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  10 in total

Review 1.  TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Authors:  Alberto Matteelli; Anna Cc Carvalho; Kelly E Dooley; Afranio Kritski
Journal:  Future Microbiol       Date:  2010-06       Impact factor: 3.165

Review 2.  ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas.

Authors:  Sangjin Hong; Peter L Pedersen
Journal:  Microbiol Mol Biol Rev       Date:  2008-12       Impact factor: 11.056

Review 3.  The Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug target.

Authors:  Hyungjin Eoh; Patrick J Brennan; Dean C Crick
Journal:  Tuberculosis (Edinb)       Date:  2008-09-14       Impact factor: 3.131

4.  Inter- versus intra-molecular cyclization of tripeptides containing tetrahydrofuran amino acids: a density functional theory study on kinetic control.

Authors:  N V Suresh Kumar; U Deva Priyakumar; Harjinder Singh; Saumya Roy; Tushar Kanti Chakraborty
Journal:  J Mol Model       Date:  2012-01-12       Impact factor: 1.810

5.  N-[(6-Bromo-2-meth-oxy-3-quinol-yl)phenyl-meth-yl]-2-morpholino-N-(1-phenyl-ethyl)acetamide.

Authors:  Zhi-Qiang Cai; Gang Xiong; Shan-Rong Li; Jian-Bo Liu; Tie-Min Sun
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-07-18

6.  Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase.

Authors:  Anna C Haagsma; Ioana Podasca; Anil Koul; Koen Andries; Jerome Guillemont; Holger Lill; Dirk Bald
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

7.  N-[(R)-(6-Bromo-2-meth-oxy-quinolin-3-yl)(phen-yl)meth-yl]-N-[(S)-1-(4-meth-oxy-phen-yl)eth-yl]-2-(piperazin-1-yl)acetamide.

Authors:  Lei Yuan; Rui Wang; Chang-Yi Li; Zhi-Qiang Wang; Tie-Min Sun
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-10-12

8.  3,11-Dibromo-14-(4-chloro-phen-yl)-14H-dibenzo[a,j]xanthene dimethyl-formamide monosolvate.

Authors:  Yong Bin Song; Bo Liu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-04-21

9.  A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis.

Authors:  Gregory J Fox; Dick Menzies
Journal:  Infect Dis Ther       Date:  2013-08-02

Review 10.  Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis.

Authors:  Anuradha T Deshkar; Prashant A Shirure
Journal:  Cureus       Date:  2022-08-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.